SILVIA BIO LIMITED

Name

SILVIA BIO LIMITED

Legal name

Silvia Bio Ltd

Website

https://silviabio.com

Company type

Private

Founded year

2025

Operating status

Operating

Ownership category

akta.pro rank

Product category

Bioprocess Development Services

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro industry

PRIMARYHLAGAEAB

Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry)

Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Central Labs & Clinical Diagnostics Services (Trial Support)

Keywords

• Cell profiling services
• Mammalian cell biomanufacturing
• CHO cell optimization
• Bioprocess media additives
• Monoclonal antibody production

Headquarters

HQ city

Sheffield

HQ country

United Kingdom

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

1. Cell Profiling Services: Proprietary cell profiling technology provided as a service to biopharmaceutical companies to identify manufacturing bottlenecks in their production processes. Delivered with rapid turnaround times under 4 weeks.
2. Licensed Media Additives: Licensable small molecule media additives that improve cell productivity and product titre. Partners can license the formulations for use in their biomanufacturing processes.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Silvia Bio provides a cell profiling platform that performs live-cell, label-free, single-cell measurements of mammalian cells in chemically defined media, complemented by precision media additives — small-molecule feed supplements that can be licensed by biopharmaceutical manufacturers. The offering is aimed at accelerating CHO cell line characterization and improving upstream productivity for monoclonal antibody and biologic production.

Product overview

Silvia Bio operates as a unified platform company offering two interconnected solutions: the Cell Profiling Platform for identifying manufacturing bottlenecks in mammalian cells, and Licensable Media Additives for overcoming those bottlenecks through precision-formulated small molecules. The platform delivers rapid cell profiling data in as little as 2 weeks, enabling biopharmaceutical manufacturers to implement targeted media additives that can achieve up to 2x higher cell productivity.

Differentiator

Problem solved

Functional benefit

Products and services

• Cell Profiling Platform (service) A service offering that performs live-cell, label-free, single-cell measurements of mammalian cells (including CHO cells) in chemically defined media, using AI-driven image analysis to deliver manufacturing-relevant cell profiling data. It is aimed at biopharmaceutical manufacturers running CHO-based monoclonal antibody and biologic production who need faster cell line characterization than conventional methods.
• Licensable Media Additives

Quantifiable outcome

• 2x higher cell productivity with media additives
• +2 more outcomes

Named customers1 record

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

One partnership is on record.

• KQ LabscoreStrategic or Co-development Partner · 19 August 2025SilViA Bio has officially joined the KQ Labs Life Sciences accelerator program. This provides the company with structured support for growth and development in the life sciences sector, including access to mentorship, resources, and networking opportunities within the biotech ecosystem.

Scale indicators2 records

Recent moves3 records

Expansion highlights4 records

Broad incumbents

• Sartorius: Leading bioprocess solutions provider supplying cell culture media, bioreactors, and process analytics. Comparable as an incumbent offering integrated media and bioprocess analytics that compete with Silvia Bio's combined profiling + additive approach.
• Lonza: World's largest CDMO with a biologics offering spanning cell line construction, process development, and manufacturing. Comparable as the benchmark bioprocess services + media player that Silvia Bio must differentiate against in CHO/mAb manufacturing.
• Cytiva: Global bioprocess tools and services provider offering media, single-use technologies, and process development services. Comparable as the dominant incumbent against which Silvia Bio must position its profiling + additive platform for CHO-based biomanufacturing.
• FUJIFILM Irvine Scientific: Major supplier of cell culture media and bioprocess solutions for biopharmaceutical and cell therapy manufacturers. Comparable as an established media/additive provider whose products directly overlap with Silvia Bio's licensable media additive offering.

Direct peers

• RoosterBio: Supplier of human mesenchymal stem/stromal cell products and bioprocess media additives. Comparable in the additive/media component of Silvia Bio's offering, addressing cell productivity and quality in cell-based manufacturing processes.
• Synthace: Bioprocess R&D automation platform enabling cloud-based experiment design, execution, and analysis for life sciences. Comparable as a technology-enabled bioprocess development platform targeting similar biopharma R&D customers with a software/services hybrid model.
• Culture Biosciences: Cloud-based bioprocess development platform running customer bioreactor experiments and providing bioprocess data analytics. Comparable in its combination of bioprocess experimentation services with data/analytics tailored to mammalian cell manufacturing optimization.
• KBI Biopharma: Contract development and biomanufacturing organization offering cell line development, process development, and analytical services for biologics. Directly comparable as a services-led player helping biopharma customers optimize mammalian cell bioprocess performance, including CHO-based programs.
• BioCentriq: CDMO focused on cell and gene therapy process development and manufacturing services. Comparable as a services organization that helps biopharma customers develop and optimize cell-based manufacturing processes.

Emerging players

• Invert Bioprocessing: Early-stage company applying computational and high-throughput biology to bioprocess and cell line engineering. Comparable as a similarly nascent technology player targeting the same bottleneck-identification pain point in mammalian cell biomanufacturing.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks7 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about SILVIA BIO LIMITED